Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Aileron Therapeutics Inc (ALRN) NPV

Sell:$0.43 Buy:$0.44 Change: $0.02 (4.49%)
NASDAQ:0.69%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.43
Buy:$0.44
Change: $0.02 (4.49%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.43
Buy:$0.44
Change: $0.02 (4.49%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.

Contact details

Address:
490 Arsenal Way
WATERTOWN
02472-2870
United States
Telephone:
+1 (617) 9950900
Website:
www.aileronrx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALRN
ISIN:
US00887A1051
Market cap:
$12.21 million
Shares in issue:
27.81 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Jeffrey Bailey
    Chairman of the Board
  • Manuel Aivado
    President, Chief Executive Officer, Director
  • Rick Wanstall
    Vice President, Finance and Operations and Principal Accounting Officer, Principal Financial Officer
  • D. Allen Annis
    Senior Vice President - Research
  • Kira Nelson
    Vice President - Finance, Vice President - Operations
  • Vojislav Vukovic
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.